NovaBay Pharmaceuticals Q3 2023 Earnings Report

NovaBay Pharmaceuticals EPS Results

• Actual EPS: -$12.95
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

NovaBay Pharmaceuticals Revenue Results

• Actual Revenue: $3.27 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

NovaBay Pharmaceuticals Announcement Details

• Quarter: Q3 2023
• Date: 11/9/2023
• Time: N/A

NovaBay Pharmaceuticals (NYSE:NBY), a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.